Video

View G. Steven Burrill's Presentation from BioConference Live
November 17, 2009.

View video 

Podcast

Jerry Flanagan, healthcare policy director for ConsumerWatchdog, discusses his group’s lawsuit against Anthem Blue Cross of California over its rate hikes, what they mean for healthcare reform, and why the proposed healthcare legislation wouldn’t have prevented Anthem from instituting the rate increases in the first place.
Hear the podcast 

G. Steven Burrill

Welcome from the CEO

Flash required to view this video. Download the latest version here

 G. Steven Burrill 
 
Sign up for a free subscription to The Burrill Weekly Brief 
Sign up to receive email notifications about our upcoming events and news.


Burrill Media is the creator, sponsor and facilitator of over a dozen leading industry conferences worldwide and publishes a wide range of bio-intelligence reports. Annual conferences include The Biotech Meeting, The Indiana Life Sciences Forum, The Burrill Personalized Medicine Meeting, The Aging Meeting and The Stem Cell Meeting. Burrill Media publications  include the annual State of the Industry, The Personalized Medicine Report, The Stem Cell Report, and periodic newsletters covering Canada, China, Europe, India, Japan and Partnering/M&A. Burrill also publishes The Burrill Report, a monthly digital publication.

20 Years of Burrill Biotech CD-ROM



We are just over 30 years into the biotechnology revolution. Following the emergence of the first biotechnology companies in the 1970s, three events in 1980 stimulated the emergence of biotech as an industrial sector in the United States and around the world. First, the pivotal Supreme Court decision of Ananda v. Chakrabarty allowed that genetically manipulated organisms could be patented. Second, the U.S. Congress passed the Bayh-Dole Act, allowing recipients of federal research funding to secure patents. Third, Genentech the first publicly traded biotechnology company set a record in its initial public offering, as its stock price soared from $35 to $89 per share in 20 minutes. Within five years, almost 700 biotech companies were founded in the United States, and about 150 went public.

Since these early heady days of the biotechnology revolution, the industry has grown, evolved, faced numerous challenges and obstacles, survived, and prospered. Biotechnology continues to thrive, playing a critically important role in introducing innovative products and practices to the market and to allied industries. Biotech today is stronger than ever, and its future prospects have never looked brighter.


Add to cart$699.00